SKAP2 Modulator Patient Stratification for IBD
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapeutic options for inflammatory bowel diseases (IBD), such as Crohn's disease and ulcerative colitis, are limited, particularly for patients with moderate to severe forms who do not respond to anti-TNF therapy, and there is a need for targeted treatments that address the underlying immunopathogenesis.
Innovation Solution
Modulating the activity or expression of Src Kinase Associated Phosphoprotein 2 (SKAP2) using specific modulators, identified through genetic analysis of single nucleotide polymorphisms (SNPs), to treat IBD patients, particularly those with moderate to severe Crohn's disease, ulcerative colitis, or ulcerative colitis, by determining the presence of specific SNPs associated with subclinical phenotypes and administering a modulator to reduce SKAP2 activity or expression.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If anti-TNF therapy is administered to IBD patients, then inflammation is reduced, but nearly half of patients do not respond or experience loss of response over time
Solution Approach 1:
The patent segments the IBD patient population into distinct subgroups based on SKAP2 genotype (presence or absence of specific SNPs). This segmentation allows for tailored therapeutic approaches where SKAP2-modulating agents are prescribed to patients with the specific genotype, thereby improving treatment response reliability for the targeted subgroup rather than applying a universal anti-TNF approach to all patients.
Solution Approach 2:
The patent applies local quality by matching specific therapeutic agents (SKAP2 modulators) to specific patient subpopulations defined by their genetic characteristics. Instead of a uniform treatment approach, the therapy is localized to patients with the appropriate SKAP2 genotype, optimizing efficacy for that specific group while acknowledging heterogeneity in the overall patient population.
2Measurement precision
If targeted therapy based on SKAP2 genotype is implemented, then treatment precision is improved, but diagnostic complexity increases due to SNP analysis requirements
Solution Approach 1:
The patent extracts the critical genetic information (SKAP2 SNP status) from the complex genomic landscape and uses it as the sole or primary basis for treatment decision-making. By focusing on this specific genetic marker rather than analyzing the entire genome or multiple markers, the patent simplifies the diagnostic process while maintaining high precision in patient stratification.
Solution Approach 2:
The patent changes the diagnostic parameter from broad phenotypic assessment or multiple genetic markers to a specific genetic parameter (SKAP2 SNP presence/absence). This parameter change simplifies the diagnostic approach while improving precision in identifying patients who will respond to SKAP2-modulating therapies.
Data Source
AI summary
Described herein are methods, systems, compositions, and kits useful for the diagnosis and/or treatment of a disease or condition in a subject. The present disclosure relates to methods and systems for identifying and stratifying patients suitable for treatment with a SKAP2 modulator, as described herein.